ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
308.3 ^USD	+2.74%		+6.97%	+8.92%

Apr. 26	UBS Adjusts ICON Price Target to $380 From $368, Maintains Buy Rating	MT
Apr. 25	Transcript : ICON Public Limited Company, Q1 2024 Earnings Call, Apr 25, 2024

ICON Public Limited Company Reaffirms Earnings Guidance for the Full Year 2024

February 21, 2024 at 04:15 pm EST

ICON Public Limited Company reaffirmed Earnings Guidance for the Full Year 2024. For the year, the company expects revenue guidance in the range of $8,400 million - $8,800 million, representing a year over year increase of 3.4% to 8.4%.

Latest news about ICON Public Limited Company

UBS Adjusts ICON Price Target to $380 From $368, Maintains Buy Rating	Apr. 26	MT
Transcript : ICON Public Limited Company, Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
ICON Q1 Adjusted EPS, Revenue Rise, 2024 Guidance Range Narrowed	Apr. 24	MT
Earnings Flash (ICLR) ICON Reports Q1 EPS $3.47, vs. Street Est of $3.41	Apr. 24	MT
Earnings Flash (ICLR) ICON Reports Q1 Revenue $2.09B, vs. Street Est of $2.088B	Apr. 24	MT
ICON Public Limited Company Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Icon CFO Brennan to Depart for Outside Opportunity	Apr. 03	DJ
Icon Says CFO Brennan Leaving in Q4, Reaffirms Guidance	Apr. 03	MT
Brendan Brennan to Resign as Chief Financial Officer of ICON Public Limited Company in Fourth Quarter 2024	Apr. 03	CI
Icon plc Reaffirm Earnings Guidance for the Year 2024	Apr. 03	CI
Transcript : ICON Public Limited Company Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM	Mar. 12
Transcript : ICON Public Limited Company Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 11:10 AM	Mar. 05
Evercore ISI Adjusts Price Target on ICON to $350 From $325, Keeps Outperform Rating	Feb. 23	MT
UBS Adjusts ICON Price Target to $368 From $295, Maintains Buy Rating	Feb. 23	MT
Mizuho Securities Ups Price Target on ICON to $346 From $315, Keeps Buy Rating	Feb. 23	MT
Barclays Adjusts Price Target on ICON to $355 From $325, Maintains Overweight Rating	Feb. 23	MT
Truist Securities Raises Price Target on ICON to $367 From $357, Maintains Buy Rating	Feb. 23	MT
ICON Shares Rise After Q4 Results, Guidance Reaffirmed	Feb. 22	MT
Deutsche Bank Raises ICON Price Target to $345 From $320, Maintains Buy Rating	Feb. 22	MT
ICON Seeks M&A	Feb. 22	CI
Transcript : ICON Public Limited Company, Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
ICON Q4 Adjusted Earnings, Revenue Increase; 2024 Guidance Affirmed	Feb. 21	MT
ICON Public Limited Company announces an Equity Buyback for $500 million worth of its shares.	Feb. 21	CI
Earnings Flash (ICLR) ICON Posts Q4 Revenue $2.07B, vs. Street Est of $2.09B	Feb. 21	MT
Earnings Flash (ICLR) ICON Reports Q4 EPS $3.46, vs. Street Est of $3.45	Feb. 21	MT

Chart ICON Public Limited Company

Duration

Period

More charts

Company Profile

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

Sector

Biotechnology & Medical Research

Calendar

2024-07-23 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for ICON Public Limited Company

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

308.3 USD

Average target price

354.1 USD

Spread / Average Target

+14.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B
BIO-TECHNE CORPORATION	-16.98%	10.07B

Other Biotechnology & Medical Research